# Accessing Meds, State of Medicaid and Patient Management Tools

Authored and Presented by: LT Neelam Gazarian, MS, PharmD LCDR Jonathan Owen, PharmD

Quentin N. Burdick Memorial Health Care Facility

Indian Health Service

Belcourt, ND

#### Conflict of Interest Disclosure Statement




#### **Objectives**

- Participants will be exposed to ideas to approach their state medicaid with regards to drug access issues
- At the end of the presentation participants will be better equipped to manage hepatitis C patients at their service unit



http://www.hepatitiscentral.com/wp-content/uploads/2015/04/expenisive-hepatitis-c-medication.jpg http://aph.org.ua/wp-content/uploads/2016/08/Bez-nazvanyya-4.png









#### Medicaid Letter - Balancing Act

Medicaid letter.pdf



#### Prior to HCV Clinic



## Success Story ND Medicaid and Expansion





Drop minimum fibrosure score requirements







12-months abstinence requirements remains




No NS5A resistance test required unless prescribing Zepatier®



#### Identifying Patients with Hepatitis C



#### Inter-collaborative Approach




#### Challenges in Starting Clinic

Labs do not exist in system

#### Fibrosure Test

#### NS5A Resistance Test

#### **EHR Documentation**



### Consults

Snapshot add

#### Hep C Order Menu

and the second se	10				
RPMS-EH		HEPATITIS C LAB PANEL		Done	
Lock Clear Demo,Patic 90010 Privacy File Vie <del>w</del>	Hep C Screen IF POSITIVE OR KNOWN HISTORY OF HCV DO HCV RNA QT REFLEX GENOTYPE Lab values required within past 3 months	Hep C PCR QUANT			iealti MED jumn LIST
View Orders Active Orders	Chem 14 CBC/Auto Diff Fibrotest PT/INR Anemia Panel Vitamin D	HIV Screen Hepatitis A Total Antibody Hepatitis B Surface Antibody Hepatitis B Core Antibody Hepatitis B Surface Antigen	Must have at least 2 UDS in last 12 months at least 3 months apart Urine Drug Screen Pregnancy Test		Duration
Delayed Orde	Alpha Fetoprotein Tumor Marker Hepatitis C Order Set Initial Tests	Hepatitis C 4 weeks and ETR labs	Hepatitis C 8 week labs All other labs		Start: 04/21/17 Stop: 04/22/18 Start: 04/21/17 Stop: 04/22/18

#### **EHR Note Templates**

C HCV Treatment Program: Initial Visit with Patient

C HCV Treatment Program: Comprehensive Visit with Patient

the state of the s

C HCV Treatment Program: Initiation of Treatment Visit with Patient

HCV Treatment Program: Continuation of Treatment Visit with Patient

C HCV Treatment Program: End of Treatment Visit with Patient

HCV Treatment Program: Three Months Post Completion of Treatment

#### **Managing Patients**

Excel document for patient management

Created by Jessica Leston, Brigg Reilley, and David Stephens

Automatically calculates APRI, FIB 4 scores

Excellent for helping to prioritize patients based on liver function and viral load

#### **Managing Patients**

List Panel Patient U Hepatitis

New panel created by Neelam 'Nelly' to help manage patients referred to the clinic

Spin-off of previous panel, automatically calculates APRI, FIB 4 scores

Organized by stage in the treatment processes

Reminders for labs while in treatment, immunizations, notes

### **Managing Patients**

Snapshot of stage in treatment process drop down menus (these can be adjusted)

White: Unable to contact Green Ready to present to ECHO Blue Started treatment Yellow Pending Appt need labs Red\_UDS Positive Purple Medication Approval Pending Orange Completed treatment, pending SVR labs Grey CURED

#### Appointment Calendar

OCTC 2017	OBER	NUTE:		ENTER MONTH: ENTER YEAR: ENTER START DAY:	october 2017 Sunday		
Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	
01	02 Smith,Jane: 12345 doe,john: 12348	03	04	05	06	<b>07</b> doc.j: 12347	
08 0	09	10	11	12	<b>13</b> smith.m: 123	14	
15 smith,b: 111	16	<b>17</b> smith,d: 1543	18	19	20	21	
22	23	24	25	26	27	28	
29	30	31					

#### Patient Panel

NICE PROJECT NORTHERN TIER INITIATIVE for HEPC ELIMINATION	NICE Project- Northern Tier Initiative for Hep C Elimination Hepatitis C Patient Panel List Developed by: LT Neelam 'Nelly' Gazarian, PharmD. QNBMHCF, Belcourt ND with LCDR Jonathan Owen, PharmD. email: neelam.gazarian@ihs.gov, jonathan.owen@ihs.gov												NICE Project- Northern Tier Initiative for Hep C Hepatitis C Patient Panel List Developed by: LT Neelam 'Nelly' Gazarian, Pharm with LCDR Jonathan Owen, PharmD. email: neelam.gazarian@ihs.gov, jonathan.owen@ihs.						
					Date for Next				>0.7 APRI likely fibrosis or cirrhosis			dvanced fibrosis, advanced fibrosis							
atient Name	ID	DOB	Patient Status	Age in 2017	Appt	AST/SGOT	ALT SGPT	Platelets	1940 970 V	APRI Stage (FIB 4		FIB 4 Stage Calc	Viral Load	Genotype	Labs ordered	Notes			
mith,Jane	12345	3/3/1986	Pending Appt need labs	31	10/2/2017	140	180	250	1.4	3	1.293938	1	3800000		Sheet1!A1	HARVO			
mith,s	12346		Already started treatment	56	11/5/2017	48	48	299	0.401337793	1	1.2975899	1	4100000	1a or 1b	Sheet2!E2	FO, Exp			
oe,j	12347	1/2/1981	May need Beh Health Consult	36	10/7/2017	42	60	348	0 301724138	1	0.56091483	1	200	unknown	Sheet3IA1	Medic			
oe,john	12348	1/3/1977	Pending Appt need labs	40	10/2/2017	28	36	297	0.235690236	1	0.6285073	1	18000000	2b	Sheet4!A1	Expan			
mith,m	123	1/4/1987	Ready to present to ECHO	30	10/13/2017	30	41	239	0.313807531	1	0.58810203	1	200	1-1-1	Sheet5!A1	Expan			
mith,a	1234		Pending Appt need labs	2	11/14/2017	484	624	223	5.426008969	3	0.17377136	1	370000	1a or 1b	Sheet6!A1	Medic			
mith,b	111	1/6/1933	Purple Medication Approval Pending	84	10/15/2017	96	104	169	1.420118343	3	4.67893643	3		1a or 1b	Sheet7IA1				
mith,c	1112	1/7/1945	Ready to present to ECHO	72	11/16/2017	50	70	333.5	0.374812594	1	1.2902018	1	430000	1a	Sheet8!A1	echo 9			
mith,d	1549	1/8/1965	Already started treatment	52	10/17/2017	34	31	195.6	0.434560327	1	1.62342625	3	2600	1	Sheet9!A1	Medic			
uck,donald	1456		Medication Approval Pending	0	9/26/2017	55	41	277	0.496389892	1	0	1	920000	1a or 1 b	Sheet101A1				
louse,Mickey	78946		Already started treatment	62	8/1/2017	38	42	177	0.536723164	1	2.05389092	3	9200000	2b	Sheet11!A1	2b EPG			
nouse,Minnie	4568		Pending Appt need labs	18		105	133	212	1.238207547	3	0.77303672	1			Sheet12!A1	Expan			
an,peter	45566		Already started treatment	51		43	56	345	0.311594203	1	0.84942595	1	4400000	1	Sheet13!A1	1a or			
oppins,Mary	4848		Completed treatment, pending SVR labs	29		47	67	211	0.556872038	1	0.78917987	1		#REF!	Sheet14!A1	Harvo			
Vonka, Willy	89621		Cannot contact	73			37		#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		#REF!	Sheet15!A1	no ins			
ree,Willy	4576		May need Beh Health Consult	25		50	110	244		1	0.4884542		4000000		Sheet16IA1	medic			
oe,a	4562	A CONTRACT OF A	Pending Appt need labs	32		88	216	314.5	0.699523052	1	0.60923539		3600	1	Sheet17!A1	expan			
oe,b	78956	12/12/1986		30					#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	15000	3	Sheet18!A1	no ins			
oe,c	7778		Cannot contact	62		48	54	230	0.52173913	1	1.76079263	3		2	Sheet19!A1	expan			
oe,d	98686		Ready to present to ECHO	19		129	116	78	4.134615385	3	2.91755945	3	120000		Sheet20!A1	no ins			
oe,e	8587		Medication Approval Pending	52	ä	95	150	204	1.164215686	3	1.9772025	3		1	Sheet211A1	medic			
oe,f	78456		Ready to present to ECHO	67		96	90	268	0.895522388		2.52982213				Sheet22!A1	Expan			
oe,g	32625	1/22/1961	Pending Appt need labs	56					#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!			Sheet23!A1	Expan			

#### Individual Patient Data

	Labs to Order Date Ordered Select from Menu		Date Ordered Select from Menu		Date Hep A 2nd Sh					Date 2nd Shot 1 month	Date 3rd Shot 6 months	Twinrix Shot	Date Twinrix 2nd shot	Twir 3rd s		
ł	HCV Screen								6/28/1900				6/28/1900		1/28/1900	5/27/
ł	HCV Viral Load		Pick from	drop down			4				1			1		
ł	HCV GT	11/20/2017														
1	NS5A Resistance			+			Enter [	Date		Enter	Date			Enter Date		
F	Pregnancy Test	11/20/2017	Negative				MM/D	D/YYYY		MM/	DD/YYYY			MM/DD/Y	m	
ł	HIV Screen	11/20/2017			< Pick fro	om drop down										
(	Chem 14															
(	СВС															
F	PT/INR				Hep B	Ab/Shot , If no										
1	Anemia Panel		Hep A se	rology/shot	please g	ive shot and f/u	-									
1	Vit D			drop down	f	or series										
ł	AFP Marker			1	Pick from	drop down										
F	Fibrotest			+												
ł	Hep A Ab					•										
	Hep B s Ab															
	Hep B s Ag				1											
ł	Hep B core Ab				1											
l	UDS				< Pick fro	om drop down	-					0				
		Enter Date> MM/DD/YYYY			Treatment Start Date		HCV RNA I			Link to Ongoi		ng Patients				
	At 4 week			1/28/1900	At 4 week				Pick from	drop	down					
	HCV Viral Load	2			5			Order	8 week Labs							
	Chem 14								8 week Labs							
(	CBC											-				
		4											-		-	
	At 8 weeks			2/25/1900	At 8 week	s			< Pick from	drop	down					
	HCV Viral Load															
	Chem 14											-			-	
(	CBC	2					-									
																L
	At ETR			3/24/1900	At ETR				< Pick from	drop	down					
	HCV Viral Load	7.					-									
	Chem 14															
(	CBC															
-													-			
	At SVR			6/16/1900	At SVR				< Pick from	drop	down					
	HCV Viral Load															
(	Chem 14											-				
1	CBC															

#### NICE Hep C Tool Demo

NICE Project- Hep C Patient Management.xlsm

Navigating Insurance

#### Stage of fibrosis score

• APRI, FIB 4

Abstinence

• Differs by state

#### Patient Assistance Program

#### Gilead's Support Path


• Sovaldi<sup>®</sup>, Harvoni<sup>®</sup>, Epclusa<sup>®</sup>

#### AbbVie Patient Assistance Foundation


• Viekira Pak®, Mavyret®

#### Patient Assistance Programs


- Tribal ID card
- Income documents
  - Max income allowed differs by program
- Proof of no insurance
  - American Indians/Alaska
    Natives (AI/AN): Indian Health
    Coverage Exemption
- "American Indians and Alaska Natives (AI/ANs) and other people eligible for services through the Indian Health Service, tribal programs, or urban Indian programs (like the spouse or child of an eligible Indian) **don't** have to pay the fee for not having health coverage. This is called having an Indian health coverage exemption."




# **Screening Rates**



#### **Investment Cost Analysis**



#### **Cost Analysis of Medications**



#### Acknowledgement

Quentin N. Burdick Memorial Health Care Facility Eliminate Hepatitis C Team:

- Neelam Gazarian, PharmD. MS Pharmacology/Toxicology
- LCDR Jonathan Owen, PharmD. USPHS
- Thanks to:
- Molly Steen, PharmD. Pharmacy Clinical Services Director
- CDR Tyler Lannoye, PharmD. Chief of Pharmacy, USPHS

### Special Thanks

- Jessica Leston, HCV/HIV/STI Clinical Programs Director for the Northwest Portland Area Indian Health Board
- Brigg Reilley, National HIV/AIDS Program
- David Stephens, BSN, RN, Case Manager for the Northwest Portland Area Indian Health Board.

# Questions



#### Thank you

Contact Info:

Neelam.Gazarian@ihs.gov

Jonathan.Owen@ihs.gov

701-477-6111 Ext 8426